Nektar misses in breast cancer

Nektar Therapeutics (NASDAQ:NKTR) said etirinotecan pegol ( NKTR-102) missed the primary endpoint of an improvement in median overall survival in the Phase III BEACON trial in metastatic breast cancer.

Patients treated with 145 mg/m2 of etirinotecan pegol once every three weeks had a 2.1 month median OS benefit over physician's choice of a single chemotherapy agent (12.4 months vs. 10.3 months; HR=0.87; p=0.08). The compound also missed its secondary endpoints of improvement in overall response rate (ORR) and progression-free survival (PFS). Patients in the trial had received a median of three prior chemotherapies for metastatic disease. ...